Table 1 Basic characteristic of the patients with primary hepatic malignant vascular tumor
Variables | PHA | EHE | MHP | IHE |
|---|---|---|---|---|
No. of patients | 11 | 15 | 3 | 13 |
Gender | ||||
Male | 4 (36%) | 2 (13%) | 1 (33%) | 6 (46%) |
Female | 7 (64%) | 13 (87%) | 2 (67%) | 7 (54%) |
Age, median, y (range) | 52 (39–74) y | 41 (29–69) y | 47 (32–55)y | 3 (0.2–24)m |
Clinical symptom | ||||
Upper abdominal pain | 4 (36%) | 4 (27%) | 2 (67%) | 0 |
Loss of appetite and weight | 4 (36%) | 1 (7%) | 0 | 0 |
Fever | 1 (9%) | 1 (7%) | 0 | 2 (15%) |
Jaundice and diarrhea | 1 (9%) | 0 | 0 | 3 (23%) |
Growth retardation | 0 | 0 | 0 | 1 (8%) |
Thrombocytopenia | 0 | 0 | 0 | 1 (8%) |
Abdominal mass | 0 | 0 | 0 | 6 (46%) |
Asymptomatic patient | 1 (9%) | 3 (20%) | 1 (33%) | 0 |
Medical history | ||||
Hepatitis-B/ Cirrhosis | 3 (27%) | 1 (7%) | 0 | 0 |
CHD | 2 (18%) | 1 (7%) | 0 | 0 |
Hypertension | 4 (36%) | 3 (20%) | 0 | 0 |
Diabetes | 3 (27%) | 3 (20%) | 0 | 0 |
Treatment strategy | ||||
Hepatectomy | 5 (45%) | 15 (100%) | 2 (67%) | 13 (100%) |
TACE | 1 (9%) | 0 | 0 | 0 |
Radiofrequency ablation | 1 (9%) | 0 | 0 | 0 |
Chemotherapy | 2 (18%) | 0 | 0 | 0 |
Antiangiogenic therapy | 1 (9%) | 0 | 0 | 0 |
Postoperative chemotherapy | 1 (9%) | 0 | 1 (33%) | 0 |
Median survival time, months | 15 | 88 | 23 | 96 |